- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00418236
Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density
Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW
It has been shown that women who have dense breasts have an increased risk of breast cancer compared with women whose breasts are less dense. However, while breast density may be a risk factor, the etiology of the relationship between breast cancer and breast density is not understood. Furthermore, it is well recognized that breast cancer can still develop in women whose breasts are not dense.
At menopause, the amount of breast glandular tissue and stroma naturally decreases due to a lack of hormonal stimulation. This is characterized as a decrease in the mammographic density. Although certain medications, including hormone therapy (HT) and dopamine antagonists can increase breast density, these effects are reversible upon discontinuation of the specific agent. Other medications such as the selective estrogen receptor modulators (SERM), raloxifene (RAL) and tamoxifen, have been shown to not affect breast density and allow the normal age-related changes to occur. The effects of bazedoxifene (BZA), a new SERM, on breast density are not known. The purpose of this study is to examine the effect of BZA on breast density changes over 24 months in postmenopausal women. The results may be useful for clinicians to understand the effect of BZA on breast density and its mammographic effects.
This is an observational, multicenter, double-blind, randomized, placebo- and active comparator-controlled study. It is also an ancillary that will use women who are already participants in a phase 3 trial for fracture reduction (protocol 3068A1-301-WW; primary study). In the primary study, subjects received BZA 20 mg, BZA 40 mg, RAL 60 mg, or placebo. This ancillary study will request a subset of participants to use their mammograms taken in this study. Their mammogram will be digitized by a central imaging center. A single radiologist will perform the quantifications of breast density from the digitized mammograms.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Buenos Aires, Argentina
-
-
-
-
-
Goiania, Brasilien, 74175-080
-
Mato Grosso, Brasilien, 78008-400
-
-
Sao Paulo
-
Sorocaba, Sao Paulo, Brasilien, 18095-458
-
-
-
-
-
Sofia, Bulgarien, 1431
-
Sofia, Bulgarien, 1303
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 2N6
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1M3
-
-
Quebec
-
Quebec City, Quebec, Canada, G1V 3M7
-
Sherbrooke, Quebec, Canada, J1H 4J6
-
-
-
-
-
Santiago, Chile
-
-
-
-
-
Vejle, Danmark, DK-7100
-
-
-
-
-
Tallin, Estland, 101 28
-
Tartu, Estland, 50410
-
-
-
-
California
-
San Diego, California, Forenede Stater, 92108
-
Upland, California, Forenede Stater, 91786
-
-
Idaho
-
Meridian, Idaho, Forenede Stater, 83642
-
-
Minnesota
-
Brooklyn Center, Minnesota, Forenede Stater, 55430
-
-
Montana
-
Billings, Montana, Forenede Stater, 59101
-
Bozeman, Montana, Forenede Stater, 59715
-
-
North Dakota
-
Bismark, North Dakota, Forenede Stater, 58503
-
Fargo, North Dakota, Forenede Stater, 58104
-
Jamestown, North Dakota, Forenede Stater, 58401
-
-
South Dakota
-
Watertown, South Dakota, Forenede Stater, 57201
-
-
-
-
-
Amsterdam, Holland, 1081 HV
-
-
-
-
-
Zadar, Kroatien, 23000
-
Zagreb, Kroatien, 10000
-
-
-
-
-
Agarismo, Mexico, 11800
-
-
-
-
-
Krakow, Polen, 30510
-
Warszawa, Polen, 02-341
-
-
-
-
-
Bucharest, Rumænien, 70231
-
Cluj-Napoca, Rumænien, 3400
-
Iasi, Jud. Iasi, Rumænien, 6600
-
-
-
-
-
Johannesburg, Sydafrika, 2196
-
Parow, Sydafrika, 7500
-
Pretoria, Sydafrika
-
Somerset West, Sydafrika, 7130
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
- Each subject must have participated or is currently participating in study 3068A1 301, and must satisfy all of the following criteria
- Has completed 24 months of treatment.
- Had a mammogram at the baseline visit and at the month 24 visit, and both are original films that are technically acceptable for reading.
- Was less than or equal to 62 years of age at the time of study randomization in the primary study.
- Was at least 80% compliant with test article administration.
- Did not take any medications 6 months prior to screening in the primary study or during the first 24 months of the study that could cause a change in breast density.
- Was enrolled at a site that has at least 4 subjects meeting all of the above inclusion criteria.
- Was enrolled at a clinical site that is still participating in the primary study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Trial Manager, For Poland, WPWZMED@wyeth.com
- Ledende efterforsker: Trial Manager, For Romania, WVPIMED@wyeth.com
- Ledende efterforsker: Trial Manager, For South Africa, ZAFinfo@wyeth.com
- Ledende efterforsker: Trial Manager, For Brazil, xavierl@wyeth.com
- Ledende efterforsker: Trial Manager, For Mexico, gomezzlj@wyeth.com
- Ledende efterforsker: Trial Manager, For Canada, clintrialparticipation@wyeth.com
- Ledende efterforsker: Trial Manager, For Croatia, WPBUMED@wyeth.com
- Ledende efterforsker: Trial Manager, For Argentina, Scheima@wyeth.com
- Ledende efterforsker: Trial Manager, For Chile, scheima@wyeth.com
- Ledende efterforsker: Trial Manager, For Denmark, medinfonord@wyeth.com
- Ledende efterforsker: Trial Manager, For Estonia, WVPMED@wyeth.com
- Ledende efterforsker: Trial Manager, For Bulgaria, WVPIMED@wyeth.com
Datoer for undersøgelser
Studer store datoer
Studiestart
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 3068A1-400
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...UkendtBRCA1 mutation | Breast Cancer Invasive NosPolen
-
Aga Khan UniversityAfsluttetBrystkræft | Perforatorklap | Brysttumor | Oncoplasty | Breast-QPakistan
-
University Health Network, TorontoAfsluttetBreast Cancer Invasive Nos | Primær invasiv brystkræftCanada
-
KU LeuvenNovartisUkendtER Positive, HER2 Negative Breast Cancer NeoplasmaBelgien